Quantum computing shares jump on report U.S. to award $2bn to firms in the sector

The Trump administration may award $2 billion in grants to nine quantum-computing companies, with $1 billion already earmarked for IBM and allocations including $375 million for GlobalFoundries and $100 million each for D-Wave Quantum, Rigetti Computing and Infleqtion. The package, funded through Chips and Science Act early-stage technology money, could also include U.S. government equity stakes and is expected to be completed later. Quantum stocks jumped 7% to 19% in premarket trading on the report, while the White House is reportedly preparing a new executive order on the sector.

Analysis

This is less about quantum economics today and more about Washington creating a state-backed option on a strategic technology stack. The market’s first-order reaction is to re-rate the named beneficiaries, but the second-order effect is a higher probability of capital reallocation toward “national champion” structures in deep tech, which lowers financing risk for a narrow subset of players while raising it for everyone else that lacks policy relevance. The biggest hidden winner may be adjacent infrastructure vendors and system integrators, because grant money tends to flow into procurement, lab build-outs, and specialized components before it becomes durable end-demand.

The competitive dynamic is uneven. IBM gets the clearest de-risking because it can absorb grants into an existing enterprise roadmap, while smaller names likely see more volatile, headline-driven upside than fundamental improvement. For public investors, the key question is whether this becomes a one-off subsidy or a repeatable federal buying cycle; if the latter, quantum suppliers could move from “science project” multiples to semi-strategic infrastructure multiples over 12-24 months. That said, the dispersion in ticker sensitivity suggests the market may be overpricing the binary beneficiaries and underpricing the execution risk for companies still years away from commercialization.

The main reversal risk is political rather than technological: delays, scope changes, or an executive-order rollout that is more signaling than funding could deflate the premarket spike within days. More important over the next 3-9 months, grant dollars may not convert into revenue fast enough to justify the move for cash-burning names, especially if the broader risk tape weakens and investors refocus on dilution and burn rates. The contrarian read is that this is bullish for the ecosystem but not necessarily for the highest-beta public equities; the cleanest expression may be in infrastructure exposure or in pairs versus other unprofitable quantum names not selected by policy.

Key Decisions for Investors

• Buy IBM on any intraday pullback after the open; use a 3-6 month horizon and treat this as a lower-volatility policy de-risking trade with asymmetric downside protection versus the smaller quantum names.
• Avoid chasing QBTS and RGTI strength outright; if already long, trim 25-50% into the opening move and keep only a smaller lottery ticket position given the high probability of mean reversion if implementation details disappoint over the next 1-4 weeks.
• Pair trade: long IBM / short a basket of unprofitable quantum high-beta names (QBTS, RGTI) for 1-3 months, betting that capital concentration and balance-sheet quality matter more than headline momentum once the initial news fades.
• Watch GFS as an indirect picks-and-shovels beneficiary; a small tactical long makes sense only if you expect incremental government-funded capex to spill into advanced manufacturing demand over 6-12 months, otherwise the move may be overextended relative to earnings impact.
• For more aggressive accounts, consider selling out-of-the-money puts on IBM rather than buying calls; premium should remain supported by elevated event-driven volatility, with a better risk/reward than chasing upside after a policy headline.